Magnus Dahlman is specialized in intellectual property law. He represents large and small clients in a wide variety of complex intellectual property matters, providing strategic advice on identifying, developing, protecting and commercializing intellectual property rights.
Magnus is an experienced litigator and has litigated several landmark cases especially within life sciences and tech patents but also trademark, trade secrets and copyright. Magnus is also regularly handling regulatory issues in the life science and telecom field and issues relating to various kinds of certifications.
Magnus has been ranked by several ranking institutes in the categories Patent Contentious and Intellectual Property and has also recently been acting as counsel in the first mock trial under the UPC rules in the Nordic Baltic regional division arranged by the Swedish Department of Justice, and is now a registered representative before the UPC.
Magnus is a co-author to the first and second edition of Hasselblatt (ed.) ”Community Trade Mark Regulation – English Language Commentary” and Hasselblatt (ed.) ”Community Design Regulation – English language commentary” published by the German publishing house C. H Beck Hart Nomos.
- Commercialization of IPR
- Dispute resolution and Litigation
- Domain names
- IP law disputes
- Intellectual property law
- Media and Market law
- Outsourcing of IPR functions
- Trade secrets
- Trademarks and trade names
- Life Sciences
- Pharmaceutical Industry
Malmö District Court
Sony Ericsson Mobile Communications AB
Lund University, LL.M.
Master Intellectual Property Rights
The EUs Machine Directive and CE-marking
- Swedish Bar Association
- AIPPI (Member of Standing Committee Q242 Pharma & Biotechnology)
The Legal 500
"Magnus Dahlman is a highly experienced and knowledgeable litigator with an eminent flair for presenting cases in a thorough and detailed fashion."
"Magnus Dahlman and Mattias Malmstedt are simply top-tier litigators, with a solid understanding of their clients businesses. The team is very competent and business minded. Straightforward advice is combined with an academic touch."
IAM Patent 1000
"An absolutely brilliant and phenomenal litigator. His knowledge of regulatory issues brings an added dimension to the practice."
"Outstanding litigator and skilled advocate” Dahlman has both the law and the technology on lock: “He is efficient, responsive and really understands his clients’ business."
"A premier choice for life science briefs and a tough adversary, Magnus has a keen eye for detail and calmly puts forth convincing arguments."
"Dahlman […] is a repository of unshakeable trust for generic drug companies. ‘He understands the industry and is an experienced, calm, tactical and convincing litigator."
"The outfit has brought on board life sciences doyen Magnus Dahlman. “Magnus hasn’t been there long”, one peer remarks, “but he has already worked with us in litigation on numerous occasions as well as having been an instrumental adviser to his clients on the commercial aspects of their businesses"
"He presents well, is clear in his arguments, has very sound judgement and shows plenty of enthusiasm for the law."
(2016, 2017 & 2018)
- Delay of the start of the sunrise period
- Judges for the Unified Patent Court have been appointed
- Preliminary date set for the start of the UPC
- The road ahead for reaching the Unitary Patent
- An unusual request for a preliminary ruling in a patent infringement case – can a defendant go forum shopping (or not)?
- Unitary Patent – A closer look at the costs after grant
- Opting out – a decision to start considering
- UP and UPC are about to happen (again)
- A new pharmaceutical strategy for Europe